A randomized, open label study of the effect of Peginterferon alfa-2a (40KD) (PEGASYS) plus entecavir (Baraclude) combination therapy on quantitative changes in HBeAg in treatment-naive patients with HBeAg positive chronic hepatitis B.
Phase of Trial: Phase IV
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Entecavir (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 09 Jun 2016 Planned no. of patients is given as 219 in NCT, however I have retained 218 as per the results published in the Clinical Infectious Diseases (3146603)
- 16 Apr 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 25 Mar 2010 Planned number of patients changed from 228 to 210 as reported by Roche record.